Repurchase of Implantica AG own shares until April 6, 2023
Implantica AG (publ) has from 29 March 2023 until 6 April 2023 completed repurchases of own shares (Swedish Depository Receipts representing class A shares in the company) as follows:
| Date: | Trading venue: | Number of shares: | Weighted average share price per day (SEK): | Total daily transaction value (SEK): |
| 28 March 2023 | SSME | 7’500 | 22.00 | 164’985.15 |
| 29 March 2023 | SSME | 2’500 | 22.32 | 55’808.20 |
| 30 March 2023 | SSME | 2’500 | 23.56 | 58’905.73 |
| 31 March 2023 | SSME | 2’500 | 22.89 | 57’230.55 |
| 3 April 2023 | SSME | 2’500 | 22.55 | 56’382.83 |
| 4 April 2023 | SSME | 2’500 | 22.04 | 55’107.55 |
| 5 April 2023 | SSME | 2’500 | 22.16 | 55’404.20 |
| 6 April 2023 | SSME | 2’500 | 21.96 | 54’893.50 |
On 22 March 2023, Implantica announced a share buy-back programme of up to a maximum of 200’000 shares based on the authorisation granted by Implantica’s 2022 Annual General Meeting. The repurchase may be conducted on one or more occasions until the next Annual General Meeting on May 25, 2023. The repurchased Shares will be used for honoring share-based incentive programs for employees and board members of the company.
After the above-mentioned transactions Implantica owns a total of 25’000 own shares.
For further information, please contact:
Nicole Pehrsson, Chief Corporate Affairs Officer
Telephone (CH): +41 (0)79 335 09 49
nicole.pehrsson@implantica.com
Implantica is listed on Nasdaq First North Premier Growth Market in Stockholm.
The company's Certified Adviser is FNCA Sweden AB, info@fnca.se
The information was sent for publication, through the agency of the contact person set out above, on April 6, 2022, at 7:30 p.m. CEST.
About Implantica
Implantica is a medtech group dedicated to bringing advanced technology into the body. Implantica’s lead product, RefluxStop™, is a CE-marked implant for the prevention of gastroesophageal reflux that will potentially create a paradigm shift in anti-reflux treatment as supported by successful clinical trial results. Implantica also focuses on eHealth inside the body and has developed a broad, patent protected, product pipeline based partly on two platform technologies: an eHealth platform designed to monitor a broad range of health parameters, control treatment from inside the body and communicate to the caregiver on distance and a wireless energising platform designed to power remote controlled implants wirelessly through intact skin. Implantica is listed on Nasdaq First North Premier Growth Market (ticker: IMP A SDB). Visit www.implantica.com for further information.
Newsroom